Corrigendum to "PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives" [Cancer Treat. Rev. 131 (2024) 102850]

Affiliations

¹ Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy; Department of Internal Medicine and Medical Specialties (Di.M.I), University of Genoa, Genoa, Italy.
² Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
³ Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Italy; Oncology Department, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Milan, Italy.
⁴ Neurosurgery Unit, Head-Neck and NeuroScience Department, University Hospital of Udine, P.le S. Maria della Misericordia, 33100 Udine, Italy.
⁵ Department of Radiation Oncology, Sant'Andrea Hospital, University of Rome Sapienza, Via Grottarossa 1035, 00189 Rome, Italy.
⁶ Sorbonne Université, AP-HP, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, DMU Neurosciences, Service de Neuro-Oncologie-Institut de Neurologie, F-75013 Paris, France.
⁷ Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ 85013, USA.
⁸ Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerand.
⁹ Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
¹⁰ Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. Electronic address: giuseppe.lombardi@iov.veneto.it.

Published Erratum

Eugenia Cella et al. Cancer Treat Rev. 2025 Jan.

. 2025 Jan:132:102866.

doi: 10.1016/j.ctrv.2024.102866. Epub 2024 Dec 21.

¹ Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy; Department of Internal Medicine and Medical Specialties (Di.M.I), University of Genoa, Genoa, Italy.
² Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
³ Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Italy; Oncology Department, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Milan, Italy.
⁴ Neurosurgery Unit, Head-Neck and NeuroScience Department, University Hospital of Udine, P.le S. Maria della Misericordia, 33100 Udine, Italy.
⁵ Department of Radiation Oncology, Sant'Andrea Hospital, University of Rome Sapienza, Via Grottarossa 1035, 00189 Rome, Italy.
⁶ Sorbonne Université, AP-HP, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, DMU Neurosciences, Service de Neuro-Oncologie-Institut de Neurologie, F-75013 Paris, France.
⁷ Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ 85013, USA.
⁸ Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerand.
⁹ Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
¹⁰ Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. Electronic address: giuseppe.lombardi@iov.veneto.it.

No abstract available

Erratum for

PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives.
Cella E, Bosio A, Persico P, Caccese M, Padovan M, Losurdo A, Maccari M, Cerretti G, Ius T, Minniti G, Idbaih A, Sanai N, Weller M, Preusser M, Simonelli M, Lombardi G. Cella E, et al. Cancer Treat Rev. 2024 Dec;131:102850. doi: 10.1016/j.ctrv.2024.102850. Epub 2024 Nov 5. Cancer Treat Rev. 2024. PMID: 39531943 Review.